argenex SE $ARGX Stock Position Increased by Park Avenue Securities LLC

Park Avenue Securities LLC raised its position in argenex SE (NASDAQ:ARGX) by 157.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 2,461 shares of the company’s stock after purchasing an additional 1,505 shares during the period. Park Avenue Securities LLC’s holdings in argenex were worth $2,360,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ARGX. WPG Advisers LLC grew its holdings in shares of argenex by 17.8% during the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after buying an additional 13 shares during the last quarter. Mather Group LLC. lifted its position in argenex by 19.1% during the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after acquiring an additional 13 shares during the period. Farther Finance Advisors LLC lifted its position in argenex by 3.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock worth $363,000 after acquiring an additional 13 shares during the period. NewEdge Advisors LLC lifted its position in argenex by 2.8% during the 1st quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock worth $382,000 after acquiring an additional 14 shares during the period. Finally, Nvwm LLC grew its stake in shares of argenex by 1.3% in the 3rd quarter. Nvwm LLC now owns 1,538 shares of the company’s stock valued at $1,475,000 after purchasing an additional 20 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Guggenheim dropped their target price on argenex from $1,185.00 to $1,120.00 and set a “buy” rating on the stock in a report on Friday, October 23rd. HC Wainwright upped their price target on argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of argenex in a report on Friday, September 25th. Piper Sandler lifted their price objective on shares of argenex from $1,075.00 to $1,215.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Finally, UBS Group upgraded shares of argenex from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $960.00 to $1,400.00 in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, argenex has a consensus rating of “Moderate Buy” and an average price target of $1,158.76.

argenex Stock Performance

ARGX opened at $892.87 on Friday. The business’s fifty day moving average is $943.61 and its two-hundred day moving average is $854.82. The company has a market cap of $56.15 billion, a price-to-earnings ratio of 31.15, a PEG ratio of 0.82 and a beta of 0.44. argenex SE has a one year low of $661.85 and a one year high of $1,072.75.

argenex (NASDAQ:ARGX) last posted its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The company had revenue of $1.75 billion for the quarter. On average, analysts predict that argenex SE will post 28.63 EPS for the current fiscal year.

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.